- India’s drugs regulator on Sunday gave final approval for the emergency use of a two-dose coronavirus vaccine, COVISHIELD, developed by AstraZeneca and Oxford University. The regulator did not discuss the recommended intervals between shots.
But in late-stage trial data published in the Lancet on Dec. 12, the company said most participants had delays in receiving their second shot. AstraZeneca said last month it did not know the reason for the higher efficacy rate, but it was preparing further tests to confirm whether the half-dose regimen could be 90% effective.The UK Medicines and Healthcare products Regulatory Agency has approved a two-full-dose regimen.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.